Metha Biofund

Solving conflict of interest in biomedical research with a #blockchain powered funding platform.#DeSci #research #funding #ethereum #lifespan #healthspan

[Metha Biofund @MBiofund]

What if research grants were released automatically once pre-registered outcomes are verified on-chain? No committees, no politics — milestone-based smart contracts could make this real. 🧬 https://t.co/lsmxBmCzV7

[Metha Biofund @MBiofund]

~50% of clinical trials are never published — mostly those with negative results. This distorts meta-analyses, misleads clinicians, and wastes billions in duplicated failed research. 💸 https://t.co/MBlRHO01U7

[Metha Biofund @MBiofund]

ResearchHub lets researchers earn RSC tokens for publishing open papers, writing peer reviews, and replicating studies — a GitHub for science where contributions are tracked and rewarded. ⛓️ https://t.co/f2uDYeZIPF

[Metha Biofund @MBiofund]

Casgevy, the first CRISPR-based gene therapy for sickle cell disease, was FDA-approved in Dec 2023. In trials, 97% of patients had zero severe pain crises for 12+ months. 🔬 https://t.co/XAz1EgUopX

[Metha Biofund @MBiofund]

Decentralized funding pools let backers support specific research directions — no gatekeepers, no overhead. Capital reaches early-stage projects faster. Researchers retain IP control. Transparency built in. 🧬 https://t.co/8wp2yUxdSD

[Metha Biofund @MBiofund]

NIH R01 grant success rates fell from ~30% in 2000 to ~20% by 2023. Researchers spend an average of 44 days per application. Is this system designed to fund science — or to exhaust scientists? 💸 https://t.co/w9xE9KAIPK

[Metha Biofund @MBiofund]

IP-NFTs allow researchers to tokenize intellectual property before patent filing — enabling community funding of early-stage science without losing ownership. DeSci is rethinking who controls discovery. ⛓️ https://t.co/vTHYM9mX78

[Metha Biofund @MBiofund]

Trastuzumab deruxtecan cut disease progression risk by 49% in HER2-low breast cancer — a subgroup representing ~60% of all cases, previously ineligible for HER2-targeted therapy. 🔬 https://t.co/6rPx5uoASN

[Metha Biofund @MBiofund]

Decentralized science DAOs are replacing grant committees with on-chain governance: any researcher, patient, or domain expert can vote on which projects get funded. Transparent, fast, borderless. 🧬 https://t.co/TVbLWUQc0p

[Metha Biofund @MBiofund]

VitaDAO has co-funded 22+ longevity research projects using IP-NFTs — token holders co-own the resulting IP. No institutional gatekeeping. No 18-month grant cycle. Science moves faster. ⛓️ https://t.co/dS86ySa18w

[Metha Biofund @MBiofund]

@davidasinclair Isn't geroprotector actually a thing ?

https://t.co/RH1SyZDvC6

Also, Senolytic.

[Metha Biofund @MBiofund]

Glial Cells and the Propagation of Tau through the Brain in Tauopathies https://t.co/hEeNTdqRaG

[Metha Biofund @MBiofund]

Exercise as an Approach to Slow Alzheimer's Disease https://t.co/0ESJg8kd5K

[Metha Biofund @MBiofund]

Molecular programs of fibrotic change in aging human lung https://t.co/WnqvmrxVqw

[Metha Biofund @MBiofund]

How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Khavinson Peptides for Thymic Regrowth https://t.co/KUmvWcBnjp

[Metha Biofund @MBiofund]

The NLRP3 Inflammasome in Osteoporosis https://t.co/PLp6z2YwuU

[Metha Biofund @MBiofund]

Exosome Treated Macrophages Improve Regeneration Following Spinal Cord Injury in Mice https://t.co/AJU9yrvx1g

[Metha Biofund @MBiofund]

Design principles and biological applications of red-emissive two-photon carbon dots https://t.co/RiMW6rSnrh

[Metha Biofund @MBiofund]

Paradoxical implication of BAX/BAK in the persistence of tetraploid cells https://t.co/No7bbv9NFB

[Metha Biofund @MBiofund]

Fight Aging! Newsletter, November 1st 2021 https://t.co/H3tjFRZlw2